Lien Lybaert

Dr. Lien Lybaert


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
Lien LybaertLien Lybaert
Lien Lybaert
KVKarim Vermaelen
Karim Vermaelen
BGBruno G. De Geest
Bruno G. De Geest
LNLutz Nuhn
Lutz Nuhn

3 May 2017 in Chemistry of Materials
Verified
Journal Article
Closed access
Lien LybaertLien Lybaert
Lien Lybaert
KRKeun Ah Ryu
Keun Ah Ryu
LNLutz Nuhn
Lutz Nuhn
RRRiet De Rycke
Riet De Rycke
OWOlivier De Wever
Olivier De Wever
BGBruno G. De Geest
Bruno G. De Geest

2 May 2017 in Advanced Science
Verified
Journal Article
Open access
PDF file
Lien LybaertLien Lybaert
Lien Lybaert
KRKeun Ah Ryu
Keun Ah Ryu
RRRiet De Rycke
Riet De Rycke
ACAlfred C. Chon
Alfred C. Chon
OWOlivier De Wever
Olivier De Wever
BGBruno G. De Geest
Bruno G. De Geest
Targeting the immune system with a personalized vaccine containing cues derived from the patient's malignancy might be a promising approach in the fight against cancer. It includes neo‐antigens as well as nonmutated tumor antigens, preferentially leading to an immune response that is directed to a broader range of epitopes compared to strategies involving a single antigen. Here, this paper reports on an elegant method to encapsulate whole cancer cells into polyelectrolyte particles. Porous and nonaggregated microparticles containing dead cancer cells are obtained by admixing mannitol and live cancer cells with oppositely charged polyelectrolytes, dextran sulfate (anionic polysaccharide), and poly‐l‐arginine (cationic polypeptide) prior to atomization into a hot air stream. It shows that the polyelectrolyte‐enrobed cancer cells, upon redispersion in phosphate buffered saline buffer, are stable and do not release cell proteins in the supernatant. In vitro experiments reveal that the particles are nontoxic and strongly increase uptake of cell lysate by dendritic cells. In vitro assessment of antigen presentation by dendritic cells reveal the potential of the polyelectrolyte‐enrobed cancer cells as promotors of antigen cross‐presentation. Finally, it is demonstrated that the immunogenicity can be enhanced by surface adsorption of a polymer‐substituted TLR7‐agonist.

15 August 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
LPLena Pfitzer
Lena Pfitzer
GBGitta Boons
Gitta Boons
Lien LybaertLien Lybaert
Lien Lybaert
WCWim van Criekinge
Wim van Criekinge
CBCedric Bogaert
Cedric Bogaert
BFBruno Fant
Bruno Fant
Background: Antigen-targeting immunotherapies hinge on the accurate identification of immunogenic epitopes that elicit robust T-cell responses. However, current computational approaches focus primarily on MHC binding affinity, leading to high false-positive rates and limiting the clinical utility of antigen selection methods. Methods: We developed the neoIM (for “neoantigen immunogenicity”) model, a first-in-class, high-precision immunogenicity prediction tool that overcomes these limitations by focusing exclusively on overall CD8 T-cell response rather than MHC binding. neoIM, a random forest classifier, was trained solely on MHC-presented non-self peptides (n = 61.829). Its performance was assessed against that of currently existing alternatives on several in vitro immunogenicity datasets. In addition, its clinical impact was investigated in two retrospective analyses of clinical trial data by assessing the effect of neoIM-based antigen selection on the positive immunogenicity rate of personal vaccine designs. Finally, the potential for neoIM as a biomarker was investigated by assessing the correlation between neoIM scores and overall survival in a melanoma patient cohort treated with checkpoint inhibitors (CPI). Results: neoIM was found to substantially outperform publicly available tools in regards to in vitro benchmarks based on ELISpot assays, with an increase in predictive power of at least 30%, reducing false positives and improving target selection efficiency. In addition, using neoIM scores during patient-specific antigen prioritization and selection was shown to yield up to 50% more clinically actionable antigens for individual patients in two recent clinical trials. Finally, we showed that neoIM could further refine response prediction to checkpoint inhibition therapy, further demonstrating the importance of evaluating neoantigen immunogenicity. Conclusions: These findings establish neoIM as the first computational tool capable of accurately predicting epitope immunogenicity beyond MHC affinity. By enabling more precise target discovery and prioritization, neoIM has the potential to accelerate the development of next-generation antigen-based immunotherapies.